Learning from Peer Assessment: The Role of the External Quality Assurance Multilaboratory Thrombophilia Test Process

Emmanuel J. Favaloro

doi:10.1055/s-2005-863809

Seminars in Thrombosis and Hemostasis, Table of Contents

Semin Thromb Hemost 2005; 31(1): 85-89
DOI: 10.1055/s-2005-863809

Learning from Peer Assessment: The Role of the External Quality Assurance Multilaboratory Thrombophilia Test Process

Emmanuel J. Favaloro¹

¹Senior Scientist in Charge, Haemostasis Laboratories, Department of Haematology, Institute of Clinical Pathology and Medical Research (ICPMR), Westmead Hospital, Westmead, New South Wales, Australia

Abstract

ABSTRACT

The quality control process is a critical feature of pathology best practice. In addition to internal quality control processes applied on a test-to-test or day-to-day basis, the participation of laboratories in external quality assurance programs (QAPs) is critical to achieving ongoing test accuracy. There are several such programs operating in the international arena. With respect to thrombophilia, these include the Australia-based Royal College of Pathologists of Australia QAP, the United Kingdom-based National External Quality Assessment Service, and the International Thrombophilia External Quality Assessment Scheme, based in the Netherlands. Although there are some similarities between the programs, some diversity is also apparent. Each of the programs assess for the common markers of congenital thrombophilia, such as antithrombin, protein C, protein S, and activated protein C resistance. Testing of some acquired markers of thrombophilia, such as lupus anticoagulant, and genetic tests such as factor V Leiden and prothrombin G20210A mutation, are also available. This report focuses on some recent trends from these programs.

KEYWORDS

Protein C - protein S - antithrombin - activated protein C resistance - lupus anticoagulant - laboratory assessment - survey - hemostasis testing - diagnostic practice - quality control

Full Text

References

REFERENCES

1 Bertina R M. Genetic approach to thrombophilia. Thromb Haemost. 2001; 86 92-103
2 Simioni P. The molecular genetics of familial venous thrombosis. Baillieres Best Pract Res Clin Haematol. 1999; 12 479-503
3 Thiagarajan P, Shapiro S S. Lupus anticoagulants and antiphospholipid antibodies. Hematol Oncol Clin North Am. 1998; 12 1167-1192
4 Van Cott E M, Laposata M. Laboratory evaluation of hypercoagulable states. Hematol Oncol Clin North Am. 1998; 12 1141-1166
5 Rao A K, Kaplan R, Sheth S. Inherited thrombophilic states. Semin Thromb Hemost. 1998; 24(suppl 1) 3-12
6 Field S L, Brighton T A, McNeil H P, Chesterman C N. Recent insights into antiphospholipid antibody-mediated thrombosis. Baillieres Best Pract Res Clin Haematol. 1999; 12 407-422
7 Haematology R CPA. QAP contact and program details. Available at: www.rcpaqap.com.au/. Accessed July 20 2004
8 UK NEQAS: NEQAS contact and other details. Available at: www.ukneqasbc.org/. Accessed July 20 2004
9 ECAT: ECAT contact and other details. Available at: www.ecat.nl/. Accessed July 20 2004
10 CAP: CAP contact and other details. Available at: www.cap.org/apps/cap.portal. Accessed July 20 2004
11 Favaloro E J, Smith J, Petinos P, Collecutt M, Street A, Hertzberg M. on behalf of the RCPA Quality Assurance Program (QAP) in Haematology Scientific Haemostasis Advisory Panel . Laboratory testing, diagnosis and management of von Willebrand's disease: Current practice in Australasia. Am J Clin Pathol. 1999; 112 712-719
12 Favaloro E J, Smith J, Petinos P, Hertzberg M, Koutts J. on behalf of the RCPA Quality Assurance Program (QAP) in Haematology Haemostasis Scientific Advisory Panel . Laboratory testing for von Willebrand's disease: an assessment of current diagnostic practice and efficacy by means of a multi-laboratory survey. Thromb Haemost. 1999; 82 1276-1282
13 Favaloro E J, Thom J, Baker R. on behalf of the Australasian Society for Thrombosis and Haemostasis Emerging Technologies Group . Assessment of current diagnostic practice and efficacy in testing for von Willebrand's disease: Results from the second Australasian laboratory survey. Blood Coagul Fibrinolysis. 2000; 11 729-738
14 Favaloro E J, Bonar R, Sioufi J et al.. Laboratory diagnosis of von Willebrand Disorder: current practice in the Southern Hemisphere. Am J Clin Pathol. 2003; 119 882-893
15 Favaloro E J, Bonar R, Kershaw G et al.. Laboratory diagnosis of von Willebrand's disorder: quality and diagnostic improvements driven by peer review in a multi-laboratory test process. Haemophilia. 2004; 10 232-242
16 Favaloro E J, Bonar R, Sioufi J et al.. Multilaboratory testing of thrombophilia: current and past practice in Australasia as assessed through the Royal College of Pathologists of Australasia Haematology Quality Assessment Program. Semin Thromb Hemost. 2005; 31 49-58
17 Favaloro E J, Wong R, Silvestrini R, McEvoy R, Jovanovich S, Roberts-Thompson P. A multilaboratory peer assessment quality assurance program-based evaluation of anticardiolipin antibody and beta₂-glycoprotein I antibody testing. Semin Thromb Hemost. 2005; 31 73-84
18 Hertzberg M, McDonald D, Neville S, Favaloro E J. External quality assurance of DNA testing for thrombophilic mutations. Am J Clin Pathol 2005 (in press)
19 Jennings I, Kitchen S, Woods T AL, Preston F E, Greaves M. Clinically important inaccuracies in testing for the lupus anticoagulant: an analysis of results from three surveys of the UK NEQAS for Blood Coagulation. Thromb Haemost. 1997; 77 934-937
20 Preston F E, Kitchen S, Jennings I, Woods T A. A UK National External Quality Assessment scheme (UK NEQAS) for molecular genetic testing for the diagnosis of familial thrombophilia. Thromb Haemost. 1999; 82 1556-1557
21 Jennings I, Kitchen S, Woods T A, Preston F E. Normalization does not improve between-laboratory agreement but may improve specificity of some assays for activated protein C resistance. Blood Coagul Fibrinolysis. 1999; 10 451-453
22 Jennings I, Kitchen S, Cooper P C, Rimmer J E, Woods T A, Preston F E. Further evidence that activated protein C resistance affects protein C coagulant activity assays. Thromb Haemost. 2000; 83 171-172
23 Jennings I, Greaves M, Mackie I J, Kitchen S, Woods T A, Preston F E. UK National External Quality Assessment Scheme for Blood Coagulation. Lupus anticoagulant testing: improvements in performance in a UK NEQAS proficiency testing exercise after dissemination of national guidelines on laboratory methods. Br J Haematol. 2002; 119 364-369
24 Jennings I, Kitchen S, Smith J, Woods T A, Preston F E. Between-centre agreement in homocysteine assays: experience from the UK NEQAS proficiency testing scheme. Thromb Haemost. 2002; 87 921-922
25 Jennings I, Kitchen S, Cooper P, Makris M, Preston F E. Sensitivity of functional protein S assays to protein S deficiency: a comparative study of three commercial kits. J Thromb Haemost. 2003; 1 1112-1114
26 Jennings I, Kitchen S, Woods T AL, Preston F E. Multilaboratory testing in thrombophilia through the United Kingdom National External Quality Assessment Service (Blood Coagulation) Quality Assurance Program. Semin Thromb Hemost. 2005; 31 66-72
27 Meijer P, De Maat M PM, Kluft C, Haverkate F, Van Houwelingen H C. Assessment of the long-term analytical performance of field methods in haemostasis by evaluation of results of an external quality assessment programme. Clin Chem. 2002; 48 1011-1015
28 Meijer P, Kluft C, Haverkate F, De Maat M P. The long-term within- and between-laboratory variability for assay of antithrombin, and proteins C and S: results derived from the external quality assessment program for thrombophilia screening of the ECAT Foundation. J Thromb Haemost. 2003; 1 748-753
29 Meijer P, Haverkate F. External quality assessment and the laboratory diagnosis of thrombophilia. Semin Thromb Hemost. 2005; 31 59-65
30 Favaloro E J, Orsag I, Bukuya M, McDonald D. A nine-year retrospective assessment of laboratory testing for activated protein C resistance: Evolution of a novel approach to thrombophilia investigations. Pathology. 2002; 34 348-355
31 Favaloro E J, Mirochnik O, McDonald D. Functional activated protein C resistance assays: correlation with factor V DNA analysis is better with RVVT- than APTT-based assays. Br J Biomed Sci. 1999; 56 23-33
32 Favaloro E J, Silvestrini R, Mohammed A. Clinical utility of anticardiolipin antibody assays: high inter-laboratory variation and limited consensus by participants of external Quality Assurance Programs signals a cautious approach. Pathology. 1999; 31 142-147
33 Favaloro E J, Silvestrini R. Assessing the utility of anticardiolipin antibody assays: a cautious approach is suggested by high variation and limited consensus in multi-laboratory testing. Am J Clin Pathol. 2002; 118 548-557
34 Tincani A, Allegri F, Sanmarco M et al.. Anticardiolipin antibody assay: a methodological analysis for a better consensus in routine determinations: a cooperative project of the European Antiphospholipid Forum. Thromb Haemost. 2001; 86 575-583
35 Galli M, Luciani D, Bertolini G, Barbui T. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood. 2003; 101 1827-1832
36 Galli M, Barbui T. Antiphospholipid syndrome: clinical and diagnostic utility of laboratory tests. Semin Thromb Hemost. 2005; 31 17-24
37 Lutz C T, Foster P A, Noll W W et al.. Multicenter evaluation of PCR methods for the detection of factor V Leiden (R506Q) genotypes. Clin Chem. 1998; 44 1356-1358
38 Tripodi A, Peyvandi F, Chantarangkul V, Menegatti M, Mannucci P M. Relatively poor performance of clinical laboratories for DNA analyses in the detection of two thrombophilic mutations-a cause for concern. Thromb Haemost. 2002; 88 690-691
39 Favaloro E J. Diagnostic issues in thrombophilia: a laboratory scientist's view. Semin Thromb Hemost. 2005; 31 11-16

Dr.
E. J Favaloro

Department of Haematology, Institute of Clinical Pathology and Medical Research (ICPMR)

WSAHS, Westmead, New South Wales, 2145, Australia

Email: emmanuel@icpmr.wsahs.nsw.gov.au